Pharmafile Logo

CVnCoV

CureVac’s CEO appointed to EC High Level Group

Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes

- PMLiVE

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

Boehringer Ingelheim headquarters

Boehringer signs €465m lung cancer vaccine deal

Licenses CureVac's cancer immunotherapy CV9202

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links